确定原发性中枢神经系统淋巴瘤的mri随访方案。

IF 3 3区 医学 Q2 HEMATOLOGY Annals of Hematology Pub Date : 2024-12-19 DOI:10.1007/s00277-024-06145-5
Inka K Puhakka, Kaisa L Sunela, Aino L Rönkä, Aino M Rajamäki, Ulla-Mari Arkko, Tuula M Klaavuniemi, Milla E L Kuusisto, Pekka A Jäkälä, Tuomas A Selander, Hanne K Kuitunen, Anne-Mari Kantanen, Outi M Kuittinen
{"title":"确定原发性中枢神经系统淋巴瘤的mri随访方案。","authors":"Inka K Puhakka, Kaisa L Sunela, Aino L Rönkä, Aino M Rajamäki, Ulla-Mari Arkko, Tuula M Klaavuniemi, Milla E L Kuusisto, Pekka A Jäkälä, Tuomas A Selander, Hanne K Kuitunen, Anne-Mari Kantanen, Outi M Kuittinen","doi":"10.1007/s00277-024-06145-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The optimal follow-up protocol for primary central nervous system lymphoma (PCNSL) is unclear. This is the first study to evaluate the benefit of structured follow-up imaging of PCNSL with respect to the timing of relapse.</p><p><strong>Methods: </strong>A total of 198 PCNSL patients (57.1% males) diagnosed between 2003 and 2020 were included. The data were collected retrospectively from 8 hospitals in Finland. Relapse detection details included structured follow-up imaging (sMRI) studies, additional imaging (aMRI) studies based on patients' new symptoms, and all outpatient and emergency visits. Overall survival (OS) with respect to the relapse detection method, sMRI versus aMRI, was also evaluated.</p><p><strong>Results: </strong>Relapse was diagnosed in 71 patients (35.9%), 66.1% of whom experienced relapse during the first 2 years after diagnosis. During the first year, 48.3% (14/29) of the relapses were detected via sMRI, and 51.7% (15/29) via aMRI. During the second year, the percentages were 33.3% and 66.7%, respectively. More than 5 years after the diagnosis, all the relapses were detected via aMRI. To observe one relapse during the first year, 9.4 sMRI studies were needed. Overall survival after relapse (OS2) was 4.0 months for the patients whose first relapse was detected via sMRI and 3.0 months for those whose first relapse was detected via aMRI (P = 0.203).</p><p><strong>Conclusions: </strong>We found that structured imaging was beneficial for relapse detection during the first year after PCNSL diagnosis. A minor trend towards better survival after relapse was observed for patients who experienced relapse according to structured imaging.</p>","PeriodicalId":8068,"journal":{"name":"Annals of Hematology","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Defining MRI-based follow-up protocol for primary central nervous system lymphoma.\",\"authors\":\"Inka K Puhakka, Kaisa L Sunela, Aino L Rönkä, Aino M Rajamäki, Ulla-Mari Arkko, Tuula M Klaavuniemi, Milla E L Kuusisto, Pekka A Jäkälä, Tuomas A Selander, Hanne K Kuitunen, Anne-Mari Kantanen, Outi M Kuittinen\",\"doi\":\"10.1007/s00277-024-06145-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The optimal follow-up protocol for primary central nervous system lymphoma (PCNSL) is unclear. This is the first study to evaluate the benefit of structured follow-up imaging of PCNSL with respect to the timing of relapse.</p><p><strong>Methods: </strong>A total of 198 PCNSL patients (57.1% males) diagnosed between 2003 and 2020 were included. The data were collected retrospectively from 8 hospitals in Finland. Relapse detection details included structured follow-up imaging (sMRI) studies, additional imaging (aMRI) studies based on patients' new symptoms, and all outpatient and emergency visits. Overall survival (OS) with respect to the relapse detection method, sMRI versus aMRI, was also evaluated.</p><p><strong>Results: </strong>Relapse was diagnosed in 71 patients (35.9%), 66.1% of whom experienced relapse during the first 2 years after diagnosis. During the first year, 48.3% (14/29) of the relapses were detected via sMRI, and 51.7% (15/29) via aMRI. During the second year, the percentages were 33.3% and 66.7%, respectively. More than 5 years after the diagnosis, all the relapses were detected via aMRI. To observe one relapse during the first year, 9.4 sMRI studies were needed. Overall survival after relapse (OS2) was 4.0 months for the patients whose first relapse was detected via sMRI and 3.0 months for those whose first relapse was detected via aMRI (P = 0.203).</p><p><strong>Conclusions: </strong>We found that structured imaging was beneficial for relapse detection during the first year after PCNSL diagnosis. A minor trend towards better survival after relapse was observed for patients who experienced relapse according to structured imaging.</p>\",\"PeriodicalId\":8068,\"journal\":{\"name\":\"Annals of Hematology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00277-024-06145-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00277-024-06145-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:原发性中枢神经系统淋巴瘤(PCNSL)的最佳随访方案尚不清楚。这是第一个评估PCNSL在复发时间方面结构化随访成像的益处的研究。方法:收集2003 ~ 2020年间确诊的PCNSL患者198例(男性57.1%)。回顾性收集芬兰8家医院的数据。复发检测细节包括结构化随访成像(sMRI)研究,基于患者新症状的附加成像(aMRI)研究,以及所有门诊和急诊就诊。还评估了复发检测方法(sMRI与aMRI)的总生存期(OS)。结果:71例患者复发(35.9%),66.1%的患者在确诊后的前2年内复发。在第一年,48.3%(14/29)的复发患者通过sMRI检测到,51.7%(15/29)通过aMRI检测到。第二年分别为33.3%和66.7%。诊断后5年多,所有复发均通过aMRI检测。为了观察第一年的一次复发,需要进行9.4项sMRI研究。首次通过sMRI检测到复发的患者总生存期(OS2)为4.0个月,首次通过aMRI检测到复发的患者总生存期(OS2)为3.0个月(P = 0.203)。结论:我们发现在PCNSL诊断后的第一年,结构化成像有利于复发检测。根据结构成像观察到复发的患者在复发后有较好的生存趋势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Defining MRI-based follow-up protocol for primary central nervous system lymphoma.

Background: The optimal follow-up protocol for primary central nervous system lymphoma (PCNSL) is unclear. This is the first study to evaluate the benefit of structured follow-up imaging of PCNSL with respect to the timing of relapse.

Methods: A total of 198 PCNSL patients (57.1% males) diagnosed between 2003 and 2020 were included. The data were collected retrospectively from 8 hospitals in Finland. Relapse detection details included structured follow-up imaging (sMRI) studies, additional imaging (aMRI) studies based on patients' new symptoms, and all outpatient and emergency visits. Overall survival (OS) with respect to the relapse detection method, sMRI versus aMRI, was also evaluated.

Results: Relapse was diagnosed in 71 patients (35.9%), 66.1% of whom experienced relapse during the first 2 years after diagnosis. During the first year, 48.3% (14/29) of the relapses were detected via sMRI, and 51.7% (15/29) via aMRI. During the second year, the percentages were 33.3% and 66.7%, respectively. More than 5 years after the diagnosis, all the relapses were detected via aMRI. To observe one relapse during the first year, 9.4 sMRI studies were needed. Overall survival after relapse (OS2) was 4.0 months for the patients whose first relapse was detected via sMRI and 3.0 months for those whose first relapse was detected via aMRI (P = 0.203).

Conclusions: We found that structured imaging was beneficial for relapse detection during the first year after PCNSL diagnosis. A minor trend towards better survival after relapse was observed for patients who experienced relapse according to structured imaging.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of Hematology
Annals of Hematology 医学-血液学
CiteScore
5.60
自引率
2.90%
发文量
304
审稿时长
2 months
期刊介绍: Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.
期刊最新文献
Novel ETV6::RAPGEF6 fusion gene in chronic eosinophilic leukemia: compiling evidence on the role of IL3 overexpression in tumorigenesis. A cross-sectional survey on health care professionals' approaches, challenges, and support needs when addressing life threat with recipients of an allogeneic hematopoietic stem cell transplantation and with their relatives. Prognostic impact of TET2 mutations in patients with acute myeloid leukemia: HM-SCREEN-Japan 01 and 02 study. Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion? The rare phenomenon of glomerulonephritis presentation in extra-nodal marginal zone lymphoma: summary of two cases and review of the literature.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1